Form 8-K - Current report:
SEC Accession No. 0001437749-25-001106
Filing Date
2025-01-14
Accepted
2025-01-14 16:02:03
Documents
15
Period of Report
2025-01-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tgtx20250114_8k.htm   iXBRL 8-K 25696
2 EXHIBIT 99.1 ex_765583.htm EX-99.1 38397
  Complete submission text file 0001437749-25-001106.txt   207633

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tgtx-20250114.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tgtx-20250114_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tgtx-20250114_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tgtx-20250114_pre.xml EX-101.PRE 11584
17 EXTRACTED XBRL INSTANCE DOCUMENT tgtx20250114_8k_htm.xml XML 2842
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

IRS No.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 25529379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)